Company Number: 12769239

Analysis Date: 2025-07-20 18:28 UTC

Financial Health Assessment Report for FAIRFAX INDUSTRIES LIMITED

---

1. Financial Health Score: D

Explanation:
The company's financial metrics are extremely minimal and static over the past five years, showing a persistent net asset value of just £1. This grade reflects a fragile financial position with very limited operational scale and minimal capital buffer. While the company is not in immediate distress, it shows symptoms of financial stagnation and very low resource availability.

---

2. Key Vital Signs:

Metric	Latest (2024)	Interpretation
Current Assets	£30	Extremely low, indicating minimal liquid resources
Current Liabilities	£29	Almost equal to current assets, tight liquidity
Net Current Assets (Working Capital)	£1	Barely positive, signaling very limited short-term financial cushion
Net Assets / Shareholders' Funds	£1	Minimal equity base, indicating very thin capitalization
Employees	0	No staff employed, likely very low business activity or dormant operations
Account Category	Micro	Smallest scale of business under UK filing standards

Interpretation:
FAIRFAX INDUSTRIES LIMITED maintains a "heartbeat" of financial health with net current assets positive by only £1 annually for five consecutive years. The company's working capital is essentially at break-even, meaning it has no meaningful buffer to absorb financial shocks or invest in growth. The absence of employees and the micro status suggest minimal or no active trading operations.

---

3. Diagnosis:

The company's financial condition resembles a patient with a very low metabolic rate — it is surviving but not thriving or growing. The static balance sheet figures over multiple years indicate no material business expansion or investment, and the tiny net asset base shows the company is effectively undercapitalized.

This "symptom" profile suggests the company might be a holding entity, a shell, or a business in a dormant or quasi-dormant state despite being classified as active. The negligible cash and liabilities being nearly equal show "healthy cash flow" is absent, and the company has no working capital to support any operational activities.

There are no signs of financial distress such as negative net assets or overdue filings, so the clinical picture is stable but very weak.

---

4. Recommendations:

• Capital Injection: To strengthen the financial "immune system," consider injecting additional capital to build net assets and provide working capital for operational flexibility.

• Operational Review: Conduct a strategic review of business activities. If the company is intended to be active, steps should be taken to increase turnover and profitability, such as securing clients or contracts.

• Cost Management: Even with minimal operations, ensure any expenses are tightly controlled to avoid eroding the minimal equity base.

• Financial Forecasting: Develop a cash flow forecast to monitor liquidity closely and avoid future cash crunch symptoms.

• Consider Dormancy: If the company is not trading and does not intend to trade shortly, consider filing as dormant to reduce compliance costs and administrative burden.

• Seek Professional Advice: If planning to grow or restructure, consult financial advisors to ensure adequate funding and regulatory compliance.

---